PMDA drug package insert
ベルベゾロンF点眼・点鼻液
PMDA Prescription drug · ロートニッテン株式会社 · package insert Mar 23, 2026
Key facts
| Brand names | ベルベゾロンF点眼・点鼻液 |
|---|---|
| Nonproprietary names | ベタメタゾンリン酸エステルナトリウム・フラジオマイシン硫酸塩 |
| Companies | 製造販売元／ロートニッテン株式会社 |
| Product type | Prescription drug |
| Therapeutic category | 点眼、点鼻用合成副腎皮質ホルモン・抗生物質配合剤 |
| Therapeutic category codes | 871319, 871329 |
| YJ codes | 1319813Q1057 |
| Approval numbers | 21900AMX01724000 |
| Package insert edition | 第2版 |
| Package insert date | Mar 23, 2026 |
| PMDA document key | 530304_1319813Q1057_1 |
| PMDA company code | 530304 |
At a glance
- 1–9 Package insert revisions
- 1–9 Related PMDA documents
- None Safety communications
- No PMDA review report published
- No Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: